Welcome to LookChem.com Sign In|Join Free
  • or
3,N4,N4-trimethyl-2,2-diphenyl-butanediyldiamine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

104866-75-3

Post Buying Request

104866-75-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

104866-75-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 104866-75-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,8,6 and 6 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 104866-75:
(8*1)+(7*0)+(6*4)+(5*8)+(4*6)+(3*6)+(2*7)+(1*5)=133
133 % 10 = 3
So 104866-75-3 is a valid CAS Registry Number.

104866-75-3Downstream Products

104866-75-3Relevant academic research and scientific papers

Aminoalkyl substituted urea derivatives and method of treatment

-

, (2008/06/13)

The present invention relates to novel amino alkyl substituted urea derivatives as well as their acid addition salts with pharmaceutically acceptable acids, to methods for the preparation of said derivatives and pharmaceutical compositions containing same, and a method for the treatment of tumors therewith. The novel urea derivatives have shown pronounced anti-neoplastic activity when tested against various tumor models in animals. The novel compounds of the present invention may be represented by the following formula: STR1 wherein X and Y are the same or different and are selected from the group consisting of a phenyl group, each of said phenyl groups being optionally substituted with one or two groups selected from halogen, CF3, OH, or alkoxy (1-4 C-atoms); and R1 and R2 are the same or different, and are each selected from the group consisting of lower alkyl groups having from one to four carbon atoms inclusive, or they form together with the nitrogen atom a saturated five- or six-membered heterocyclic ring; R3 and R4 are each selected from hydrogen, lower alkyl or alkenyl groups with from 1-6 carbon atoms inclusive, cyclopentyl or cyclohexyl; and n is 0 or 1, as well as pharmaceutically acceptable acid addition salts thereof. When X is different from Y and/or R3 is different from R4 the compounds of Formula I exist as optical isomers, which may be separated in the individual enantiomers, which often show the activity in different degree. These individual isomers as well as their isolation fall within the scope of the present invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 104866-75-3